Wednesday, 28 Jun 2017

You are here

Elimination of Senescent Chondrocytes Reduces Post-Traumatic Osteoarthritis

A study in the April 24 issue of Nature Medicine suggests that senescent cells in the joint contribute to age-related degenerative disease and that their removal can abrogate disease. 

Senescent cells are a normal part of wound healing and injury repair. Senescent chondrocytes are found in cartilage tissue isolated from patients undergoing joint replacement surgery. But senescent cells combined with trauma or aging may contribute to the problem. 

Using an animal model, OA changes were surgically induced and then researchers injected an experimental drug named UBX0101, which was recently identified to kill senescent cells in laboratory studies.

They found that senescent cells accumulated in the articular cartilage and synovium after surgery and that selective elimination of senescent cells attenuated the development of post-traumatic OA, reduced pain and increased cartilage development.

UBX0101 injected into the joints 14 days after trauma, reduced the presence of senescent cells nearly 50 percent. In addition, the researchers monitored gene expression in treated mice and found that genes associated with reparative cartilage growth were activated in the joint after treatment.

Collectively, these experiments point to senescent chondrocytes are a potential therapeutic target in treating degenerative joint disease.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Bone Turnover Markers in Practice: A Guide for the Rheumatologist

Bone turnover markers (BTMs) have been eyed for decades as potential monitoring tools in osteoporosis.

However, there have been difficulties with poor between-lab reproductivity, insufficiently controlled heterogeneity, and pre-analytical variability of the assays; making BTMs vastly unpopular amongst practicing rheumatologists.

2017 ACR Guideline on Glucocorticoid-Induced Osteoporosis

The American College of Rheumatology has updated its 2010 guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. The guideline provides recommendations on assessing fracture risk and treatment for adults and special patient populations, including women of childbearing potential, adults treated with very high-dose glucocorticoids, adults with organ transplants, and children ages 4-17.

Higher Fracture Risks with Prolonged Bisphosphonate Use in Older Women

The Journal of the American Geriatric Society has reported that older women receiving bisphosphonate therapy for greater than 10-13 years were more likely to suffer from fractures.

Chondroitin Effective in Knee OA. Or is it?

Reginster and colleagues have reported on the results of the CONCEPT trial showing that osteoarthritis (OA) patients treated 800 mg/day of  pharmaceutical-grade chondroitin sulfate (CS) have less VAS pain scores and improved function over 6 months therapy. These results were superior to placebo and equivalent to celecoxib in reducing in symptomatic OA knee pain.

High Fiber Intake May Decrease Osteoarthritis Knee Pain

 

Dai, Felson and colleagues report in Annals of Rheumatic Disease that high dietary fiber lowers the risk of symptomatic osteoathritis (SxOA), but the radiographic benefits remain unclear. (Citation source http://buff.ly/2rHv9yd)